• 学术搜索
  • 科研智能体
    • Research Labs
    • AI 阅读
    • AI 文库
    • 深度研究
    • 学者亮点
  • 学术资源
    • AI2000
    • 期刊/会议
    • 学者库
    • 学术API
      MCP&Skill
    • 溯源树
    • 数据集
  • 知识沉淀
    • 学术空间
订阅小程序
旧版功能
aminer vip
开通会员低至0.73元/天
一次搞定AI科研
立即登录
  • English
  • 联系方式
    U

    US Oncology Network

    企业EST. 1999
    244论文总数
    1,989引用总数

    论文量&引用量时间轴

    机构学者

    论文(244)

    年份
    起
    –
    止
    排序
    1TRANSFORM-1 Phase 3 Study: Efficacy and Safety of Navitoclax Plus Ruxolitinib in Patients with Untreated Myelofibrosis.
    Naveen Pemmaraju,Adam J Mead,Tim C P Somervaille,Francesca Palandri,Steffen Koschmieder, Robert Delage,Jean-Jacques Kiladjian,Christopher B Benton,Srinivas K Tantravahi,Noa Lavi,Su-Peng Yeh,Maria Teresa Gomez Casares,

    The Phase 3 TRANSFORM-1 study (NCT04472598) evaluated ruxolitinib (RUX) in combination with navitoclax (NAV) or placebo (PBO) in Janus-kinase-inhibitor-naïve adults with intermediate-2 or high-risk myelofibrosis and Eastern Cooperative Oncology Group performance status ≤2. Patients were randomized 1:1 to NAV (200 mg/day starting dose or 100 mg escalated to 200 mg/day) or PBO, with RUX dosed per label. The primary endpoint was ≥35% spleen volume reduction (SVR) at Week 24 (SVR35W24). Secondary endpoints included change from baseline in Total Symptom Score (TSS) at Week 24 and SVR35 at any time. A total of 252 patients (NAV+RUX, n=125; PBO+RUX, n=127; median follow-up 20.3 months) were randomized; >80% had intermediate-2 risk and nearly 50% were high-molecular risk (HMR). SVR35W24 was achieved by 63.2% with NAV+RUX versus 31.5% with PBO+RUX (P<0.0001). Mean change in TSS at Week 24 was not significantly different between NAV+RUX and PBO+RUX (-10.2 vs -11.6; P=0.2852). SVR35 at any time was achieved in 76.8% with NAV+RUX versus 44.1% with PBO+RUX (nominal P<0.0001). A ≥20% variant allele frequency reduction (exploratory endpoint) occurred in 58.5% (95% CI: 49.0-67.5) with NAV+RUX and 45.5% (95% CI: 36.4-54.8) with PBO+RUX. NAV+RUX showed higher hematologic toxicity versus PBO+RUX (Grade 3/4 thrombocytopenia: 54.0% vs 19.2%; Grade 3/4 neutropenia: 40.3% vs 8.8%); diarrhea (any grade: 41.9% vs 16.8%) was also more common. Cytopenias were generally manageable and reversible with dose adjustments.

    2026Blood(2026)引用:1
    引用
    AI阅读
    加入学术空间
    2Real-world Comparative Effectiveness of Nab-Paclitaxel and Paclitaxel in Combination with Bevacizumab in Patients with Platinum-Resistant Ovarian Cancer (COMPASS)
    Robert Coleman,Raina Mathur, Anju Parthan, Prakirthi Yerram, Amanda Kesner-Hays, Rachel Myers,Iulia Cristina Tudor, Darin Dobler, Adrian Jubb, Mark Shahin
    2026GYNECOLOGIC ONCOLOGY(2026)
    引用
    AI阅读
    加入学术空间
    3From Digital Patient Navigation to Shared Care: A Clinician-Facing Platform to Bridge Academic-Community Oncology Fragmentation.
    Govind Warrier, Shannon Kehrli, Tatiana Drewiacki, Naru Sato, James Huang, Lara Yuan, Kashif Alam Firozvi, Rose Wang,Evan J. Lipson

    720 Background: Digital patient navigation can engage patients with cancer across settings, but patient-initiated navigation alone may not overcome structural barriers to subspecialty consultation, trial access, and local-academic care coordination. Building on prior work showing high engagement but limited downstream subspecialty consultation through patient-facing navigation among patients with melanoma, we implemented a clinician-facing, HIPAA-compliant Shared Care Network (SCN) to connect academic subspecialists and community oncologists across mid-Atlantic practices. We evaluated feasibility and early utility. Methods: We retrospectively evaluated the first 228 cases managed through the SCN (6 academic, 18 community organizations) from January 2025 to May 2026. Outcomes were evaluated using RE-AIM, focusing on Reach (case volume and tumor-type distribution), Effectiveness (travel time saved via local coordination and proportion of completed subspecialty consults resulting in a documented care-plan change, including therapy modification, sequencing change, or trial referral), and Adoption (new physician relationships and case initiation by setting). Data sources included platform case logs, consult recommendations, treatment decision tracking, and mileage mapping. Results: Among 228 cases, 84% were initiated by community oncologists for trial matching (60%, n=137) or informal/formal subspecialty consultation (24%, n=55), and 16% (n=36) by academic oncologists for local care coordination. Median consult response time was 2.5 hours. Among 72 unique oncologist interactions, 70% (n=50) were new relationships. Most common tumor types were advanced skin cancers (36%, n=81), gastrointestinal cancers (25%, n=56), lung cancer (11%, n=24), breast cancer (9%, n=20), genitourinary cancers (5%, n=12), hematologic malignancies (4%, n=8). Among formal subspecialty consultations (n=40), 68% (n=27) had a documented treatment decision change. Of 23 patients completing a trial screening visit via SCN referral, 11 (48%) enrolled. In locally coordinated cases with mileage data (n=29), patients saved a median of 1.5 hours driving per visit. Conclusions: In this early implementation evaluation, a clinician-facing digital Shared Care Network facilitated academic-community collaboration, with most cases initiated by community oncologists and most oncologist interactions representing new relationships. Subspecialty input frequently changed care plans, and local coordination reduced travel burden. These findings suggest that embedding clinician-facing coordination into existing workflows may address referral, trial access, and geographic barriers not overcome by patient-facing navigation alone. Prospective RE-AIM evaluation is underway assessing implementation fidelity, maintenance, trial enrollment, and scalability.

    2026JCO Oncology Practice(2026)
    引用
    AI阅读
    加入学术空间
    4P1.288: Real-World Outcomes for First-Line Nivolumab + Ipilimumab + Chemotherapy in PD-L1<1% Metastatic Non-Small Cell Lung Cancer
    M. Dietrich, L. Bazhenova, D. Waterhouse, S. Lucht, M. Brown, A. Kotomale, T. Miller, C. Omary, S. Kasbekar, S. Lucherini, B. Feinberg
    2026Journal of Thoracic Oncology(2026)
    引用
    AI阅读
    加入学术空间
    5Intraoperative Assessment of Anatomical Resection Margin Using a Novel Asymmetric Linear Stapler: an Initial Single Institution Experience
    Yooyoung Chong, Kyung-Hee Kim,Hyun Jin Cho, Calvin S H Ng, Sandeep J Khandhar, Marion Durand,Toshihiko Sato,Mingyon Mun, Min-Woong Kang

    OBJECTIVES:Intraoperative assessment of resection margins during pulmonary resection is limited by tissue compression and distortion caused by conventional staplers, which hinder direct pathological evaluation of the anatomical resection margin. We report our initial clinical experience with a novel asymmetric linear stapler (NALS) designed to provide direct access to the specimen-side anatomical resection margin for intraoperative histologic assessment. METHODS:We retrospectively reviewed patients who underwent pulmonary resection using the NALS between July 2024 and December 2025. Intraoperative frozen-section examination was performed for parenchymal and/or bronchial margins when malignancy was suspected or confirmed. Margin status, margin distance, and frozen-permanent pathological concordance were analysed descriptively. RESULTS:Among 226 patients who underwent pulmonary resection using the NALS, 206 resection margins (144 parenchymal and 62 bronchial) were evaluated. Intraoperative frozen-section examination identified margin positivity in 12 margins (5.8%). Residual tumour was confirmed on permanent pathology in 4 of 8 parenchymal frozen-positive margins, whereas all bronchial frozen-positive margins showed benign or reactive changes. No false-negative frozen-section findings were identified. Among negative margins with available measurements, 66.7% of parenchymal margins and 84.5% of bronchial margins measured at least 10 mm. CONCLUSIONS:In this initial experience, intraoperative margin assessment using the NALS was feasible and enabled structured evaluation of the anatomical resection margin during pulmonary resection. Because no control group using conventional staplers was included, these findings should be interpreted as a feasibility assessment rather than evidence of superiority over standard stapling devices. Further multicentre studies with controlled comparisons and long-term oncologic follow-up are warranted.

    2026Interdisciplinary cardiovascular and thoracic surgery(2026)
    引用
    AI阅读
    加入学术空间
    立即登录,查看全部 244 篇论文

    合作机构(100)

    Texas Oncology合作论文 31
    德克萨斯大学奥斯汀分校合作论文 17
    McKesson Corporation合作论文 15
    Virginia Oncology Associates合作论文 12
    辉瑞合作论文 11
    纪念斯隆凯特琳癌症中心合作论文 10
    New York Oncology Hematology合作论文 9
    丹娜—法伯癌症研究所合作论文 9
    默克制药公司合作论文 9
    Rocky Mountain Cancer Centers合作论文 9

    机构统计